An increased risk for subsequent primary cancers has been observed in patients with skin cancer including squamous cell carcinoma (SCC). Although the mechanism of such association has not been fully understood, several factors including immunosuppression may play a role. However, of greater focus is the risk of subsequent hematologic malignancies in patients with lip SCC which has not been previously reported. The aim of this study was to explore the risk of hematologic malignancy in lip SCC survivors. The SEER database (2000-2014) was searched to detect all patients with a primary cutaneous lip SCC who survived 2 months after diagnosis. SCC was detected by histology codes for squamous neoplasms (8050-8089) in conjunction with primary site for lip (C00.0-C00.02; C00.06; C00.08; C00.09). Site recode B ICD-O-3 was used to detect hematologic malignancy. Standardized Incidence Ratios (SIRs), ratio of the observed (O) in lip SCC survivors, to the expected (E) in the general population (O:E ratios), and 95% confidence intervals (CIs), were calculated. Of 5,537 individuals with lip SCC, 65 developed 1 primary lymphatic or hematopoietic malignancies, and particularly showing a significantly increased risk for lymphoma (O:E 1.46, 95% CI 1.04-1.99). The mean time in months to the development of a hematologic malignancy was 46 (range: 2-164 months). Interestingly, when stratified by gender, risk of subsequent lymphoma remained significant for males (O:E 1.63, 95% CI 1.14-2.25), but not for females (O:E 0.75, 95% CI 0.21-1.93). These findings that nationwide, cutaneous lip SCC survivors are at increased risk for developing primary lymphatic malignancies, especially lymphoma, warrant enhanced surveillance for lip SCC patients. In addition, exploration to determine the risk of subsequent primary malignancy in non-lip cutaneous SCC seems warranted.